Longevity Therapeutics 2019: "Enhancing & Accelerating Aging Research & The Development of Therapies Targeting Age-Related Diseases"

The inaugural Longevity Therapeutics symposium brought together leading biotech drug developers, academics, investors and pharma companies engaged in creating therapies targeting age-related conditions.

Sessions focused on specific challenges facing these efforts, including discovery, preclinical activities, translational research, clinical development, and regulatory and commercial considerations, and provided a wealth of details about the most recent developments in this space.

Longevity Therapeutics [Workshop]: "Developing A Preclinical Drug Development Pipeline in Anti-Aging"

Longevity science presents novel financial, development, regulatory, and clinical challenges to biotechnology/pharmaceutical entrepreneurs. Using one company as an exemplar, this workshop you will explored the fundamentals of launching and growing a successful biotechnology/ pharmaceutical business, with an emphasis on nuances specific to the emerging anti-aging industry.

Panel discussion: "Extending Human Lifespan" at JPM 2019

The J.P. Morgan Healthcare Conference held in San Francisco this month included a breakout session entitled “Extending Human Lifespan,” sponsored by BIOAGE and Felicis Ventures.

The centerpiece of the event was a panel discussion among five luminaries of the aging field:

  • Laura Deming, founder of Longevity Fund and Age1

  • Simon Melov, professor at the Buck Institute for Research on Aging

  • Aydin Senkut, founder and managing partner of Felicis Ventures

  • Kristen Fortney, founder and CEO of BIOAGE

  • Sonia Arrison (moderator), author of “100 Plus: How the Coming Age of Longevity Will Change Everything”

Antibiotics against senescence?

Two widely used antibiotics can kill senescent cells in vitro, illustrating the potential power of drug repurposing approaches to identify approved compounds with novel anti-aging activities.